Vanta Bioscience

Why is Vanta Bioscience Ltd falling/rising?

As of 18-Jul, Vanta Bioscience Ltd's stock price is at 25.29, unchanged from the previous session, and has underperformed its sector by 0.71%. Despite a year-to-date increase of 7.62%, the stock faces challenges due to declining trading activity and significant long-term losses.

As of 18-Jul, Vanta Bioscience Ltd's stock price is currently at 25.29, showing no change from the previous trading session. The stock has underperformed its sector by 0.71% today, indicating a relative weakness in performance. Over the past week, the stock has not experienced any price movement, remaining flat at 0.00%, while the benchmark Sensex has increased by 0.75%. <BR><BR>In the longer term, the stock has shown a modest increase of 6.48% over the past month, contrasting with the Sensex's gain of 1.29%. However, year-to-date, Vanta Bioscience has risen by 7.62%, significantly outperforming the Sensex, which has declined by 8.30%. Despite this positive year-to-date performance, the stock has faced considerable declines over the past year and beyond, with a drop of 13.80% over the last year and a staggering 82.80% over the last five years.<BR><BR>The stock is currently trading above its moving averages for 5, 20, 50, 100, and 200 days, which typically indicates a bullish trend. However, there are signs of falling investor participation, as evidenced by a significant drop in delivery volume, which decreased by 54.55% compared to the 5-day average. This decline in trading activity may contribute to the stock's inability to gain momentum despite its favorable moving averages.<BR><BR>Overall, while Vanta Bioscience Ltd has shown some positive performance metrics in the short term and is trading above its moving averages, the lack of trading activity and underperformance against its sector today suggest that the stock is currently facing challenges that may hinder its price rise.

Which are the latest news on Vanta Bioscience?

What does Vanta Bioscience do?

Vanta Bioscience Ltd is a preclinical contract research organization focused on healthcare services, with a market cap of INR 16 Cr. As of March 2023, it reported net sales of 3 Cr and a net profit of -3 Cr.

Overview: <BR>Vanta Bioscience Ltd is a preclinical contract research organization operating in the Healthcare Services industry within the Micro Cap market-cap bracket.<BR><BR>History: <BR>Vanta Bioscience Limited was originally incorporated as a Private Limited Company on 29th April 2016 and converted into a Public Limited Company on 17th March 2017. The latest quarterly results reported net sales and net profit for the period ending March 2023.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Cr (Quarterly Results - Mar 2023) <BR>Most recent Net Profit: -3 Cr (Quarterly Results - Mar 2023) <BR>Market-cap value: INR 16 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 131.00 <BR>Industry P/E: 24 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.58 <BR>Return on Equity: 0.62% <BR>Price to Book: 0.85 <BR><BR>Contact Details: <BR>Address: No.02/G/308/G Umajay Complex, Rasoolpura Secunderabad Hyderabad Telangana : 500003 <BR>Tel: 91-40-66575454 <BR>Email: info@vantabio.com <BR>Website: http://www.vantabio.com

How big is Vanta Bioscience?

As of 10th June, Vanta Bioscience Ltd has a market capitalization of 16.00 Cr, classifying it as a Micro Cap company, with recent net sales of 3.45 Cr and a net loss of 3.92 Cr for the quarter ending March 2023.

As of 10th June, Vanta Bioscience Ltd has a market capitalization of 16.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest quarter ending March 2023, Vanta Bioscience reported Net Sales of 3.45 Cr. However, the company experienced a loss of 3.92 Cr in Net Profit for the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2025. During this period, the Shareholder's Funds amounted to 10.42 Cr, while Total Assets were reported at 85.88 Cr.

Who are in the management team of Vanta Bioscience?

The management team of Vanta Bioscience includes Mohan Krishna Mulakala (Chairman), Dopesh Raja Mulakala (Managing Director), Vyasmurti Madhavrao Shingatgeri (Whole-time Director), Padmanabhuni Venkata Appaji (Independent Director), Zoheb Sayani (Company Secretary), Sadhanala Venkata Rao (Whole Time Director & CEO), and Yogeswara Rao Danda (Additional Independent Director). They are responsible for guiding the company's strategic direction and operations.

The management team of Vanta Bioscience includes the following individuals:<BR><BR>1. **Mohan Krishna Mulakala** - Chairman<BR>2. **Dopesh Raja Mulakala** - Managing Director<BR>3. **Vyasmurti Madhavrao Shingatgeri** - Whole-time Director<BR>4. **Padmanabhuni Venkata Appaji** - Independent Director<BR>5. **Zoheb Sayani** - Company Secretary<BR>6. **Sadhanala Venkata Rao** - Whole Time Director & CEO<BR>7. **Yogeswara Rao Danda** - Additional Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Who are the peers of the Vanta Bioscience?

Vanta Bioscience's peers include Tejnaksh Health, Adeshwar Meditex, Transgene Biotek, Family Care, Looks Health, Clinitech Lab, Dr. Lalchand Lab, Dhanvantri Jeev, and Gian Lifecare. Most peers exhibit below-average management and growth risks, with Looks Health showing the highest 1-year return at 85.17% and Gian Lifecare the lowest at -62.42%.

Peers: The peers of Vanta Bioscience are Tejnaksh Health., Adeshwar Meditex, Transgene Biotek, Family Care, Looks Health, Clinitech Lab, Dr Lalchand. Lab, Dhanvantri Jeev., and Gian Lifecare.<BR><BR>Quality Snapshot: Below Average management risk is observed at Tejnaksh Health., Adeshwar Meditex, Vanta Bioscience, Clinitech Lab, Dr Lalchand. Lab, Dhanvantri Jeev., and Gian Lifecare, while Average management risk is found at Family Care. Transgene Biotek and Looks Health do not qualify for management risk assessment. Below Average growth is noted at Tejnaksh Health., Adeshwar Meditex, Vanta Bioscience, Clinitech Lab, Dr Lalchand. Lab, Dhanvantri Jeev., and Gian Lifecare, with Good growth at Family Care. Transgene Biotek and Looks Health do not qualify for growth assessment. Good capital structure is present at Tejnaksh Health., Clinitech Lab, Dr Lalchand. Lab, Dhanvantri Jeev., and Gian Lifecare, while Average capital structure is found at Adeshwar Meditex, and Below Average at Vanta Bioscience.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Looks Health at 85.17%, while Gian Lifecare has the lowest at -62.42%. Vanta Bioscience's 1-year return of -17.84% is better than Gian Lifecare's but worse than Looks Health's. Additionally, the six-month return is negative for Tejnaksh Health., Family Care, Dr Lalchand. Lab, Dhanvantri Jeev., and Gian Lifecare.

When is the next results date for Vanta Bioscience Ltd?

The next results date for Vanta Bioscience Ltd is 30 May 2026.

The next results date for Vanta Bioscience Ltd is scheduled for 30 May 2026.

How has been the historical performance of Vanta Bioscience?

Vanta Bioscience has experienced significant declines in net sales and profitability, with net sales dropping to 1.96 Cr in March 2025 from 9.72 Cr in March 2024, resulting in an operating loss of -4.15 Cr and negative cash flow from operations. The company's financial position is challenging, marked by increasing liabilities and deteriorating earnings per share.

Answer:<BR>The historical performance of Vanta Bioscience has shown significant fluctuations over the years, particularly in net sales and profitability. In March 2025, net sales dropped to 1.96 Cr from 9.72 Cr in March 2024, which was a decrease from 6.28 Cr in March 2023 and 9.69 Cr in March 2022. The total operating income followed a similar trend, declining from 9.72 Cr in March 2024 to 1.96 Cr in March 2025. The company has faced increasing total expenditure, which reached 6.22 Cr in March 2025, compared to 8.41 Cr in March 2024. This led to an operating profit (PBDIT) of -4.15 Cr in March 2025, a stark contrast to the positive 1.42 Cr in March 2024. Profit before tax also worsened, recording -4.11 Cr in March 2025, down from -2.54 Cr in March 2024. Consequently, the profit after tax for March 2025 was -4.77 Cr, worsening from -2.32 Cr in March 2024. The company's earnings per share (EPS) reflected this decline, falling to -7.56 in March 2025 from -3.68 in March 2024. On the balance sheet, total liabilities increased to 85.88 Cr in March 2025, up from 85.40 Cr in March 2024, while total assets also rose to 85.88 Cr. The cash flow from operating activities turned negative at -2.00 Cr in March 2025, compared to a positive 2.00 Cr in March 2024.<BR><BR>Breakdown:<BR>Vanta Bioscience's financial performance has been characterized by a significant decline in net sales, which fell to 1.96 Cr in March 2025 from 9.72 Cr in the previous year. This decline in revenue has been accompanied by a sharp increase in total expenditure, resulting in an operating loss of -4.15 Cr in March 2025. The company's profitability metrics, including profit before tax and profit after tax, have also deteriorated, with figures of -4.11 Cr and -4.77 Cr respectively for March 2025. The earnings per share have similarly dropped to -7.56. On the balance sheet, total liabilities increased slightly to 85.88 Cr, while total assets matched this figure, indicating a challenging financial position. The cash flow from operating activities has turned negative, reflecting ongoing operational difficulties. Overall, Vanta Bioscience's financial trajectory suggests significant challenges in maintaining revenue and profitability over the recent years.

Is Vanta Bioscience overvalued or undervalued?

As of August 4, 2025, Vanta Bioscience is considered overvalued and risky due to poor financial ratios, including a PE Ratio of -3.38 and an ROE of -31.38%, alongside a year-to-date stock decline of 42.53%, significantly underperforming its peers and the market.

As of 4 August 2025, Vanta Bioscience's valuation grade has moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company is currently assessed as overvalued, given its troubling financial ratios, including a PE Ratio of -3.38, an EV to EBIT of -8.02, and an ROE of -31.38%. These figures suggest that Vanta is struggling to generate profits and is facing substantial operational challenges.<BR><BR>In comparison to its peers, Vanta's ratios starkly contrast with those of Altius Telecom, which boasts a PE Ratio of 55.44, and Embassy Off.REIT at 23.07. This highlights Vanta's underperformance within the healthcare services sector. The company's recent stock performance has also been dismal, with a year-to-date decline of 42.53%, significantly underperforming the Sensex, which has gained 3.69% in the same period. Overall, Vanta Bioscience's financial metrics and peer comparisons strongly indicate that it is overvalued in the current market environment.

Who are the top shareholders of the Vanta Bioscience?

The top shareholder of Vanta Bioscience is Mohan Krishna Mulakala, holding 55.22% of the shares. Individual investors own 26.35%, while the highest public shareholder is A Vimalchand with 1.09%.

The top shareholders of Vanta Bioscience include the promoters, with Mohan Krishna Mulakala holding the largest share at 55.22%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. The highest public shareholder is A Vimalchand, who holds 1.09%. Additionally, individual investors collectively own 26.35% of the company's shares.

What is the technical trend for Vanta Bioscience?

As of May 21, 2025, Vanta Bioscience's trend is mildly bearish, influenced by daily moving averages and Bollinger Bands, despite some bullish signals from the weekly MACD and monthly RSI.

As of 21 May 2025, the technical trend for Vanta Bioscience has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend, while the weekly MACD and KST show a mildly bullish signal. The monthly MACD and KST remain bearish, and the Bollinger Bands also reflect a mildly bearish outlook on both weekly and monthly time frames. The RSI shows no signal on the weekly but is bullish on the monthly, suggesting some potential for upward movement, although the overall sentiment leans towards bearish.

Has Vanta Bioscience declared dividend?

No Dividend History Available